Skip to main content
Entheon Biomedical Corp. logo

Entheon Biomedical Corp. — Investor Relations & Filings

Ticker · ENBI ISIN · CA29383X2023 LEI · 894500N2J7IXCCDRWU50 CSE Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2022-07-11 Regulatory Filings
Country CA Canada
Listing CSE ENBI

About Entheon Biomedical Corp.

https://www.entheonbiomedical.com/

Entheon Biomedical Corp. is a biotechnology research and development company focused on creating therapeutic solutions for addiction and substance use disorders. The company specializes in the development and commercialization of psychedelic medicines, particularly dimethyltryptamine (DMT). Entheon aims to progress psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel compounds tailored for treating these complex conditions.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2022-07-11 English
News release - English.pdf
Regulatory Filings
2022-07-11 English
Other.pdf
M&A Activity Classification · 100% confidence The document is titled 'Asset Purchase Agreement' and contains detailed contractual terms between two companies regarding the sale and purchase of assets. It includes sections on purchase price, representations and warranties, covenants, conditions, closing arrangements, indemnification, and general provisions. This is a legal agreement related to a transaction, specifically an asset purchase, rather than a financial report, regulatory filing, or announcement. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The document is clearly related to M&A activity, as it is a formal agreement for the purchase of assets between two companies. Therefore, the appropriate classification is 'M&A Activity' (Code: TAR). The document length and content confirm it is the full agreement, not just an announcement or summary.
2022-06-08 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the sale of certain clinical assets, filing of provisional patents, and termination of a financing plan. It contains no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. It is primarily an update on corporate transactions and strategic decisions. There is no indication that this is a full financial report, audit report, earnings release, or management discussion. The content fits best as a general regulatory announcement about corporate activities and transactions. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-06-07 English
Statement of executive compensation (form 51-102F6) - English.pdf
Regulatory Filings
2022-05-30 English
Other Correspondence.pdf
Regulatory Filings
2022-05-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.